SCHEMBL4132058

SCHEMBL4132058

COc1cc2c(cc1I)OCO2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
HPGD P15428 1/20 0.55
ALDH1A1 P00352 2/20 0.45
MITF O75030 1/20 0.45
HSP90AA1 P07900 1/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
POLB P06746 2/20 0.41
CYP3A4 P08684 2/20 0.41
HTR1A P08908 2/20 0.41
HTR2A P28223 2/20 0.41
HTR2C P28335 2/20 0.41
HTR2B P41595 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458653 0.84 LMNA (0.64) LMNAHPGDALDH1A1MITFHSP90AA1
SCHEMBL29198715 0.79 KCNH2 (0.40) LMNAHPGDMAPTMAPK1TSHR
SCHEMBL785194 0.77 LMNA (0.56) LMNAHPGDALDH1A1MITFHSP90AA1
SCHEMBL31709528 0.77 CYP3A4 (0.44) ALDH1A1MAPTMAPK1POLBCYP3A4
SCHEMBL1742802 0.77 CYP3A4 (0.44) ALDH1A1MAPTMAPK1POLBCYP3A4
SCHEMBL5997064 0.75 LMNA (0.55) LMNAHPGDALDH1A1MITFHSP90AA1
SCHEMBL8111501 0.75 LMNA (0.55) LMNAHPGDALDH1A1MITFHSP90AA1
SCHEMBL8803195 0.75 LMNA (0.55) LMNAHPGDALDH1A1MITFHSP90AA1
SCHEMBL30720219 0.75 LMNA (0.55) LMNAHPGDALDH1A1MITFHSP90AA1
SCHEMBL212999 0.75 LMNA (0.55) LMNAHPGDALDH1A1MITFHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117069732-B Preparation method of benzo [ c ] phenanthridine natural product and derivative thereof 沈阳药科大学 2024-04-26 CN disclosed
CN-117069732-A Preparation method of benzo [ c ] phenanthridine natural product and derivative thereof 沈阳药科大学 2023-11-17 CN disclosed
US-20230192687-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2023-06-22 US disclosed
US-11560377-B2 Fused amino pyridine as HSP90 inhibitors Guris, Inc. (US) 2023-01-24 US disclosed
US-20210292317-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2021-09-23 US disclosed
US-10844056-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2020-11-24 US disclosed
US-20200062754-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2020-02-27 US disclosed
US-10428068-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2019-10-01 US disclosed
US-20190010152-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2019-01-10 US disclosed
US-10035797-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2018-07-31 US disclosed
US-20160058742-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2016-03-03 US disclosed
US-9040556-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2015-05-26 US disclosed
US-20140221343-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. (US) 2014-08-07 US disclosed
US-8586605-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2013-11-19 US disclosed
EP-2069324-B1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2013-07-31 EP disclosed
US-8324240-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2012-12-04 US disclosed
US-20120237508-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. 2012-09-20 US disclosed
EP-2069324-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS Curis, Inc. (US) 2009-06-17 EP disclosed
WO-2008115719-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. (US) 2008-09-25 WO disclosed
US-20080234314-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190010152-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885
US-10428068-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885
US-20160058742-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885
US-20120237508-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885
US-20230192687-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885
US-20080234314-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885
US-20210292317-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885
US-20200062754-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885
US-20140221343-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885
US-11560377-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885
US-10844056-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885
US-10035797-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P LMNA 4612/4885HPGD 719/4885ALDH1A1 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.